Trial results for the Phase 2 MagnetisMM-4 study of elranatamab in combination with other anti-cancer treatments for multiple myeloma were posted on ClinicalTrials.gov on 2026-02-23. The study, which was terminated, reported dose-limiting toxicities (DLTs) in 4 participants at one dose level of the elranatamab + nirogacestat arm and 3 participants in the elranatamab + lenalidomide + dexamethasone arm.
Background
Elranatamab is being investigated for the treatment of multiple myeloma, a cancer of plasma cells.
Trial design
This Phase 2 trial (NCT05090566), titled 'MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma,' enrolled 46 participants with multiple myeloma. The study investigated elranatamab in combination with nirogacestat and also with lenalidomide plus dexamethasone. The trial's overall status is terminated.
Key results
The study assessed the number of participants experiencing dose-limiting toxicities (DLTs) during the Phase 1b dose escalation. Key findings include:
- In the elranatamab + nirogacestat arm, 0 participants experienced DLTs at Dose Level 1, 0 at Dose Level 2, 4 at Dose Level 3, 0 at Dose Level 3A, and 2 at Dose Level 4A.
- In the elranatamab + lenalidomide + dexamethasone arm, 3 participants experienced DLTs at Dose Level 1.
What this means
The reporting of dose-limiting toxicities (DLTs) across multiple dose levels and the subsequent termination of the MagnetisMM-4 study suggest that the safety profile of these elranatamab combination regimens in multiple myeloma warrants further investigation or re-evaluation. The observed DLTs in 4 participants at one dose level and 3 participants at another indicate potential challenges in identifying a recommended Phase 2 dose for these specific combinations.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05090566, titled 'MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma,' were posted on 2026-02-23 on clinicaltrials.gov.